VALN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

11.166

Open

11.030

VWAP

11.07

Vol

13.76K

Mkt Cap

965.20M

Low

10.920

Amount

152.29K

EV/EBITDA(TTM)

--

Total Shares

86.88M

EV

697.29M

EV/OCF(TTM)

--

P/S(TTM)

--

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Show More

Events Timeline

(ET)

2026-01-19

14:20:00

Valneva Voluntarily Withdraws Ixchiq Vaccine Applications

2025-12-31 (ET)

2025-12-31

11:50:00

Valneva and Serum Institute of India Terminate Chikungunya Vaccine License Agreement

2025-12-10 (ET)

2025-12-10

11:50:00

Valneva Reports Positive Final Data for IXCHIQ Vaccine

2025-08-25 (ET)

2025-08-25

06:53:04

Valneva reveals U.S. FDA has suspended IXCHIQ's license.

2025-07-29 (ET)

2025-07-29

10:31:41

Valneva signs development, manufacturing agreement with AGC Biologics

2025-06-09 (ET)

2025-06-09

09:27:09

UK restricts use of Valneva chikungunya vaccine for safety review

News

Benzinga

Latham Group Shares Surge After Strong Q4 Results

Newsfilter

03-02Newsfilter

Valneva Management to Attend Investor Conferences

seekingalpha

02-19seekingalpha

Valneva Projects €155M–€170M Revenue for 2026

Newsfilter

02-19Newsfilter

Valneva Reports 2025 Financials and 2026 Outlook

seekingalpha

02-13seekingalpha

Valneva Updates Ixchiq Vaccine Recommendations in the UK

Newsfilter

02-13Newsfilter

UK Updates IXCHIQ Vaccine Usage Recommendations

2 Analyst Rating

Wall Street analysts forecast VALN stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.55

Averages

10.28

High

13.00

Current: 0.000

Low

7.55

Averages

10.28

High

13.00

Guggenheim

Buy

downgrade

$14 -> $13

AI Analysis

2025-09-08

Reason

Guggenheim

Price Target

$14 -> $13

AI Analysis

2025-09-08

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.

Jefferies

Maury Raycroft

Buy

downgrade

$18 -> $14

2025-08-25

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $14

2025-08-25

downgrade

Buy

Reason

Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VALN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Valneva SE (VALN.O) is -8.22, compared to its 5-year average forward P/E of -233.97. For a more detailed relative valuation and DCF analysis to assess Valneva SE's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-233.97

Current PE

-8.22

Overvalued PE

465.16

Undervalued PE

-933.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.60

Current EV/EBITDA

-21.34

Overvalued EV/EBITDA

55.55

Undervalued EV/EBITDA

-54.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.73

Current PS

3.46

Overvalued PS

5.15

Undervalued PS

2.31

Financials

AI Analysis

Annual

Quarterly

Whales Holding VALN

Frazier Life Sciences Management, LP

General American Investors Company, Inc.

Novo Holdings A/S

Bpifrance Participations SA

CNP Assurances SA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Valneva SE (VALN) stock price today?

The current price of VALN is 11.11 USD — it has increased 1.28

What is Valneva SE (VALN)'s business?

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

What is the price predicton of VALN Stock?

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is10.28 USD with a low forecast of 7.55 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Valneva SE (VALN)'s revenue for the last quarter?

Valneva SE revenue for the last quarter amounts to NaN USD, decreased

What is Valneva SE (VALN)'s earnings per share (EPS) for the last quarter?

Valneva SE. EPS for the last quarter amounts to USD, decreased

How many employees does Valneva SE (VALN). have?

Valneva SE (VALN) has 676 emplpoyees as of March 06 2026.

What is Valneva SE (VALN) market cap?

Today VALN has the market capitalization of 965.20M USD.